Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide

Author(s): Haass C, Selkoe DJ

Abstract

The distinct protein aggregates that are found in Alzheimer's, Parkinson's, Huntington's and prion diseases seem to cause these disorders. Small intermediates - soluble oligomers - in the aggregation process can confer synaptic dysfunction, whereas large, insoluble deposits might function as reservoirs of the bioactive oligomers. These emerging concepts are exemplified by Alzheimer's disease, in which amyloid beta-protein oligomers adversely affect synaptic structure and plasticity. Findings in other neurodegenerative diseases indicate that a broadly similar process of neuronal dysfunction is induced by diffusible oligomers of misfolded proteins.

Similar Articles

Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease

Author(s): Goate A, Chartier-Harlin MC, Mullan M, Brown J, Crawford F, et al.

A pathogenic mutation for probable Alzheimer's disease in the APP gene at the N-terminus of beta-amyloid

Author(s): Mullan M, Crawford F, Axelman K, Houlden H, Lilius L, et al.

Apolipoprotein E and Alzheimer disease

Author(s): Strittmatter WJ, Roses AD

Apolipoprotein E controls cerebrovascular integrity via cyclophilin A

Author(s): Bell RD, Winkler EA, Singh I, Sagare AP, Deane R, et al.

Circadian rhythms, melatonin and depression

Author(s): Quera Salva MA, Hartley S, Barbot F, Alvarez JC, Lofaso F, et al.

Neurotoxins: free radical mechanisms and melatonin protection

Author(s): Reiter RJ, Manchester LC, Tan DX

The zinc dyshomeostasis hypothesis of Alzheimer's disease

Author(s): Craddock TJ, Tuszynski JA, Chopra D, Casey N, Goldstein LE, et al.

Treatment of sleep disturbance in Alzheimer's disease

Author(s): McCurry SM, Reynolds CF, Ancoli-Israel S, Teri L, Vitiello MV

Sundown syndrome in persons with dementia: an update

Author(s): Khachiyants N, Trinkle D, Son SJ, Kim KY